Evidence map›Paper›PMID 30177913›Full record

ArticleFrontiers in endocrinology2018

Oral Tongue Malignancies in Autoimmune Polyendocrine Syndrome Type 1.

Øyvind Bruserud, Daniela-Elena Costea, Saila Laakso, Ben-Zion Garty, Eirik Mathisen, Antti Mäkitie, Outi Mäkitie, Eystein S Husebye

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Øyvind BruserudDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Daniela-Elena CosteaGade Laboratory for Pathology, Haukeland University Hospital, Bergen, Norway.
Saila LaaksoChildren's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Ben-Zion GartyAllergy and Immunology Clinic, Schneider Children's Medical Center of Israel, Tel Aviv, Israel.
Eirik MathisenDepartment of Otolaryngology-Head and Neck Surgery, Østfold Hospital, Sarpsborg, Norway.
Antti MäkitieDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Outi MäkitieChildren's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Eystein S HusebyeDepartment of Clinical Science, University of Bergen, Bergen, Norway.
University of Bergen · NOUniversity of Helsinki · FIFolkhälsans Forskningscentrum · FIHaukeland University Hospital · NOØstfold Hospital Trust · NOTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) or Autoimmune polyendocrine syndrome type-1 (APS-1) (APECED, OMIM 240300) is a rare, childhood onset, monogenic disease caused by mutations in the

Indexed as

Autoimmune polyendocrine syndrome type 1Autoimmune Regulator genechronic mucocutaneous candidiasisendocrinologyoral malignancies

Identifiers

PMID30177913
PMCPMC6109689
OpenAlexW2887368054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.